AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, Maryland to launch its cell therapy platforms in the US for critical cancer trials and future commercial supply.
More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas.
The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics, AbelZeta, Cellectis, and the acquisition of Neogene Therapeutics.
Pam Cheng, Executive Vice President of Global Operations & IT and Chief Sustainability Officer, AstraZeneca, said: “We are incredibly excited that more than 150 new highly skilled jobs are being created to bring our scientific work and therapies to clinical trials which could transform the lives of patients around the world. This new $300 million investment will accelerate our ambition to make next-generation cell therapy a reality, ensuring that we are ready to scale and meet the demands of patients.”
The facility in Rockville, MD is located less than five miles away from one of the company’s five global R&D centers and sits within the booming life sciences corridor in Maryland. With close proximity to several universities, the life sciences ecosystem provides an attractive environment for recruiting new and experienced talent.
The Rockville facility will join AstraZeneca’s global manufacturing and supply network of nearly 30 manufacturing and supply sites in 16 countries, which are either currently operational or under development across the company.
In the US, AstraZeneca’s manufacturing sites focus on the production of small molecules and biologics, harnessing leading pharmaceutical technology and development. Together, the US manufacturing sites employ more than 2,600 full-time employees and deliver more than 9 billion doses of medicines annually.
